{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:51:49Z","timestamp":1777045909032,"version":"3.51.4"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-11062-5","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T18:57:39Z","timestamp":1759172259000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The effects of incretins as a double-edged sword on cancer"],"prefix":"10.1007","volume":"52","author":[{"given":"Helia","family":"Mavaddat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abtin","family":"Fouladi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirreza","family":"Peyrovinasab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Illia","family":"Khayatan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanieh","family":"Jalalian Targhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mojdeh","family":"Fakhri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamyab","family":"Andarzbakhsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietrich","family":"B\u00fcsselberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Mehrad","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Rezazadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"3","key":"11062_CR1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4103\/0019-509X.200658","volume":"53","author":"PS Roy","year":"2016","unstructured":"Roy PS, Saikia BJ (2016) Cancer and cure: a critical analysis. Indian J Cancer 53(3):441\u2013442","journal-title":"Indian J Cancer"},{"issue":"1","key":"11062_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.26444\/aaem\/94299","volume":"26","author":"AM Lewandowska","year":"2019","unstructured":"Lewandowska AM (2019) Environmental risk factors for cancer - review paper. Ann Agric Environ Med 26(1):1\u20137","journal-title":"Ann Agric Environ Med"},{"key":"11062_CR3","volume":"575","author":"Z Luo","year":"2023","unstructured":"Luo Z et al (2023) Targeting cancer metabolic pathways for improving chemotherapy and immunotherapy. Cancer Lett 575:216396","journal-title":"Cancer Lett"},{"issue":"1","key":"11062_CR4","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"11062_CR5","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1124\/pr.108.000604","volume":"60","author":"W Kim","year":"2008","unstructured":"Kim W, Egan JM (2008) The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 60(4):470\u2013512","journal-title":"Pharmacol Rev"},{"issue":"4","key":"11062_CR6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00592-019-01444-0","volume":"57","author":"CB Giorda","year":"2020","unstructured":"Giorda CB et al (2020) Incretin-based therapy and risk of cholangiocarcinoma: a nested case-control study in a population of subjects with type 2 diabetes. Acta Diabetol 57(4):401\u2013408","journal-title":"Acta Diabetol"},{"issue":"9","key":"11062_CR7","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2174\/1567201816666191010145029","volume":"16","author":"D Zhang","year":"2019","unstructured":"Zhang D, Ma M, Liu Y (2019) Protective effects of incretin against age-related diseases. Curr Drug Deliv 16(9):793\u2013806","journal-title":"Curr Drug Deliv"},{"issue":"3","key":"11062_CR8","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102427","volume":"16","author":"R Shetty","year":"2022","unstructured":"Shetty R (2022) Adverse drug reactions of GLP-1 agonists: a systematic review of case reports. Diabetes Metab Syndr 16(3):102427","journal-title":"Diabetes Metab Syndr"},{"issue":"12","key":"11062_CR9","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1210\/en.2003-0323","volume":"144","author":"L Farilla","year":"2003","unstructured":"Farilla L (2003) Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144(12):5149\u20135158","journal-title":"Endocrinology"},{"issue":"9","key":"11062_CR10","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/dom.12291","volume":"16","author":"H Zhao","year":"2014","unstructured":"Zhao H et al (2014) Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K\/Akt pathway. Diabetes Obes Metab 16(9):850\u2013860","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"11062_CR11","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.2337\/db13-1169","volume":"63","author":"T Nomiyama","year":"2014","unstructured":"Nomiyama T et al (2014) Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth. Diabetes 63(11):3891\u20133905","journal-title":"Diabetes"},{"key":"11062_CR12","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.biopha.2018.07.092","volume":"106","author":"ZJ Nie","year":"2018","unstructured":"Nie ZJ (2018) Exendin-4 inhibits glioma cell migration, invasion and epithelial-to-mesenchymal transition through GLP-1R\/sirt3 pathway. Biomed Pharmacother 106:1364\u20131369","journal-title":"Biomed Pharmacother"},{"key":"11062_CR13","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115553","volume":"140","author":"MM Helsted","year":"2020","unstructured":"Helsted MM (2020) The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. Bone 140:115553","journal-title":"Bone"},{"issue":"19","key":"11062_CR14","volume":"12","author":"Y Zhang","year":"2025","unstructured":"Zhang Y et al (2025) The novel dual GIP and GLP-1 receptor agonist Tirzepatide attenuates colon cancer development by regulating glucose metabolism. Adv Sci 12(19):e2411980","journal-title":"Adv Sci"},{"issue":"11","key":"11062_CR15","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1007\/s40618-024-02441-z","volume":"47","author":"I Caruso","year":"2024","unstructured":"Caruso I (2024) The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. J Endocrinol Invest 47(11):2671\u20132678","journal-title":"J Endocrinol Invest"},{"key":"11062_CR16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.molmet.2018.05.014","volume":"14","author":"F Kahles","year":"2018","unstructured":"Kahles F et al (2018) The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE(-\/-) mice by blocking monocyte\/macrophage activation. Mol Metab 14:150\u2013157","journal-title":"Mol Metab"},{"key":"11062_CR17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ygyno.2024.10.004","volume":"191","author":"W Kong","year":"2024","unstructured":"Kong W et al (2024) Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer. Gynecol Oncol 191:116\u2013123","journal-title":"Gynecol Oncol"},{"key":"11062_CR18","doi-asserted-by":"crossref","unstructured":"Huang L et al (2023) Tirzepatide inhibits tumor growth in mice with diet-induced obesity","DOI":"10.1101\/2023.06.22.546093"},{"key":"11062_CR19","unstructured":"Glenny EM et al (2024) Tirzepatide attenuates mammary tumor progression in diet-induced obese mice. The National Library of Medicine isrunning a pilot to include preprints that result from research funded byNIH in PMC and PubMed. BioRxiv https:\/\/pubmed.ncbi.nlm.nih.gov\/38328151\/"},{"issue":"2","key":"11062_CR20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2337\/dci22-0052","volume":"46","author":"CA Thompson","year":"2023","unstructured":"Thompson CA, St\u00fcrmer T (2023) Putting GLP-1 RAs and thyroid cancer in context: additional evidence and remaining doubts. Diabetes Care 46(2):249\u2013251","journal-title":"Diabetes Care"},{"issue":"10","key":"11062_CR21","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1007\/s00125-021-05508-1","volume":"64","author":"P Ueda","year":"2021","unstructured":"Ueda P et al (2021) Use of incretin-based drugs and risk of cholangiocarcinoma: scandinavian cohort study. Diabetologia 64(10):2204\u20132214","journal-title":"Diabetologia"},{"issue":"5","key":"11062_CR22","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/dme.14287","volume":"37","author":"J Rouette","year":"2020","unstructured":"Rouette J et al (2020) Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes. Diabet Med 37(5):868\u2013875","journal-title":"Diabet Med"},{"issue":"3","key":"11062_CR23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/dom.12605","volume":"18","author":"LM Knapen","year":"2016","unstructured":"Knapen LM et al (2016) Use of incretin agents and risk of pancreatic cancer: a population-based cohort study. Diabetes Obes Metab 18(3):258\u2013265","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"11062_CR24","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41598-023-27509-3","volume":"13","author":"A Juji\u0107","year":"2023","unstructured":"Juji\u0107 A et al (2023) Endogenous incretin levels and risk of first incident cancer: a prospective cohort study. Sci Rep 13(1):382","journal-title":"Sci Rep"},{"issue":"11","key":"11062_CR25","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1541-7786.MCR-23-0411","volume":"21","author":"JS Brown","year":"2023","unstructured":"Brown JS et al (2023) Updating the definition of cancer. Mol Cancer Research: MCR 21(11):1142\u20131147","journal-title":"Mol Cancer Research: MCR"},{"key":"11062_CR26","doi-asserted-by":"crossref","unstructured":"Ames BN, Gold LS, Willett WC (1995) The causes and prevention of cancer. Proceedings of the National Academy of Sciences, 92(12): pp. 5258\u20135265","DOI":"10.1073\/pnas.92.12.5258"},{"issue":"7467","key":"11062_CR27","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature12625","volume":"501","author":"RA Burrell","year":"2013","unstructured":"Burrell RA (2013) The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501(7467):338\u2013345","journal-title":"Nature"},{"issue":"2","key":"11062_CR28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ijc.1440","volume":"94","author":"DM Parkin","year":"2001","unstructured":"Parkin DM et al (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94(2):153\u2013156","journal-title":"Int J Cancer"},{"key":"11062_CR29","volume":"9","author":"KG de la Cruz-L\u00f3pez","year":"2019","unstructured":"de la Cruz-L\u00f3pez KG et al (2019) Lactate in the regulation of tumor microenvironment and therapeutic approaches. Front Oncol 9:1143","journal-title":"Front Oncol"},{"key":"11062_CR30","unstructured":"Lima WP PATHOPHYSIOLOGY OF CANCER. Pr\u00e1ticas corporais, sa\u00fade e ambientes de pr\u00e1tica: fatos, a\u00e7\u00f5es e rea\u00e7\u00f5es Volume II: p. 106"},{"key":"11062_CR31","unstructured":"Nogueira HS, Lima WP (2018) C\u00e2ncer, sistema imunol\u00f3gico e exerc\u00edcio f\u00edsico: uma revis\u00e3o narrativa. Corpoconsci\u00eancia, : pp. 40\u201352"},{"issue":"2","key":"11062_CR32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.canlet.2004.07.013","volume":"215","author":"T Dorai","year":"2004","unstructured":"Dorai T, Aggarwal BB (2004) Role of chemopreventive agents in cancer therapy. Cancer Lett 215(2):129\u2013140","journal-title":"Cancer Lett"},{"issue":"19","key":"11062_CR33","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM200011093431901","volume":"343","author":"M Esteller","year":"2000","unstructured":"Esteller M et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343(19):1350\u20131354","journal-title":"N Engl J Med"},{"key":"11062_CR34","first-page":"3223","volume":"21","author":"SB Jensen","year":"2013","unstructured":"Jensen SB (2013) Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients. Support Care Cancer 21:3223\u20133232","journal-title":"Support Care Cancer"},{"issue":"5","key":"11062_CR35","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/iub.2454","volume":"73","author":"R Varela-Calvi\u00f1o","year":"2021","unstructured":"Varela-Calvi\u00f1o R (2021) The mechanism of sitagliptin inhibition of colorectal cancer cell lines\u2019 metastatic functionalities. IUBMB Life 73(5):761\u2013773","journal-title":"IUBMB Life"},{"issue":"5","key":"11062_CR36","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/CM9.0000000000001363","volume":"134","author":"XX Zhu","year":"2021","unstructured":"Zhu XX (2021) Liraglutide suppresses the proliferation of endometrial cancer cells through the adenosine 5\u2019-monophosphate (AMP)-activated protein kinase signaling pathway. Chin Med J (Engl) 134(5):576\u2013578","journal-title":"Chin Med J (Engl)"},{"key":"11062_CR37","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109641","volume":"349","author":"A Chequin","year":"2021","unstructured":"Chequin A et al (2021) Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. Chem Biol Interact 349:109641","journal-title":"Chem Biol Interact"},{"issue":"3","key":"11062_CR38","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s13340-021-00560-z","volume":"13","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y (2022) Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth. Diabetol Int 13(3):480\u2013492","journal-title":"Diabetol Int"},{"key":"11062_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9101429","author":"C Rey-Re\u00f1ones","year":"2021","unstructured":"Rey-Re\u00f1ones C et al (2021) Type 2 diabetes mellitus and cancer: epidemiology, physiopathology and prevention. Biomedicines 9(10): p. 1429. https:\/\/doi.org\/10.3390\/biomedicines9101429","journal-title":"Biomedicines"},{"key":"11062_CR40","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.diabres.2018.04.002","volume":"143","author":"A Cignarelli","year":"2018","unstructured":"Cignarelli A et al (2018) Diabetes and cancer: pathophysiological fundamentals of a \u2018dangerous affair.\u2019 Diabetes Res Clin Pract 143:378\u2013388","journal-title":"Diabetes Res Clin Pract"},{"issue":"15","key":"11062_CR41","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/pros.23687","volume":"78","author":"W He","year":"2018","unstructured":"He W, Li J (2018) Exendin-4 enhances radiation response of prostate cancer. Prostate 78(15):1125\u20131133","journal-title":"Prostate"},{"issue":"5","key":"11062_CR42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/pros.23951","volume":"80","author":"H Wenjing","year":"2020","unstructured":"Wenjing H et al (2020) Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation. Prostate 80(5):367\u2013375","journal-title":"Prostate"},{"issue":"10","key":"11062_CR43","doi-asserted-by":"crossref","first-page":"e0139709","DOI":"10.1371\/journal.pone.0139709","volume":"10","author":"Y Tsutsumi","year":"2015","unstructured":"Tsutsumi Y et al (2015) Combined treatment with Exendin-4 and Metformin attenuates prostate cancer growth. PLoS ONE 10(10):e0139709","journal-title":"PLoS ONE"},{"issue":"5","key":"11062_CR44","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/jdi.13247","volume":"11","author":"T Shigeoka","year":"2020","unstructured":"Shigeoka T (2020) Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression. J Diabetes Investig 11(5):1137\u20131149","journal-title":"J Diabetes Investig"},{"issue":"2","key":"11062_CR45","first-page":"91","volume":"125","author":"XN Li","year":"2017","unstructured":"Li XN et al (2017) Glucagon-like Peptide-1 analogues inhibit proliferation and increase apoptosis of human prostate cancer cells in vitro. Exp Clin Endocrinol Diabetes 125(2):91\u201397","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"11062_CR46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173102","volume":"878","author":"S Eftekhari","year":"2020","unstructured":"Eftekhari S, Montazeri H, Tarighi P (2020) Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with docetaxel on LNCaP prostate cancer cell line. Eur J Pharmacol 878:173102","journal-title":"Eur J Pharmacol"},{"key":"11062_CR47","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2021.108851","volume":"703","author":"N Yamada","year":"2021","unstructured":"Yamada N (2021) GLP-1 reduces the migration of hepatocellular carcinoma cells via suppression of the stress-activated protein kinase\/c-Jun N-terminal kinase pathway. Arch Biochem Biophys 703:108851","journal-title":"Arch Biochem Biophys"},{"issue":"8","key":"11062_CR48","first-page":"3520","volume":"23","author":"Q Li","year":"2019","unstructured":"Li Q (2019) Liraglutide promotes apoptosis of HepG2 cells by activating JNK signaling pathway. Eur Rev Med Pharmacol Sci 23(8):3520\u20133526","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"29","key":"11062_CR49","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1038\/onc.2017.38","volume":"36","author":"M Zhou","year":"2017","unstructured":"Zhou M et al (2017) The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP\u2013PKA\u2013EGFR\u2013STAT3 axis. Oncogene 36(29):4135\u20134149","journal-title":"Oncogene"},{"issue":"12","key":"11062_CR50","doi-asserted-by":"crossref","first-page":"24293","DOI":"10.3390\/ijms141224293","volume":"14","author":"BD Chen","year":"2013","unstructured":"Chen BD et al (2013) Effect of the GLP-1 analog exendin-4 and oxaliplatin on intrahepatic cholangiocarcinoma cell line and mouse model. Int J Mol Sci 14(12):24293\u201324304","journal-title":"Int J Mol Sci"},{"issue":"6","key":"11062_CR51","volume":"13","author":"R Lu","year":"2018","unstructured":"Lu R et al (2018) Synergistic anti-tumor effects of liraglutide with Metformin on pancreatic cancer cells. PLoS ONE 13(6):e0198938","journal-title":"PLoS ONE"},{"issue":"12","key":"11062_CR52","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1507\/endocrj.EJ19-0215","volume":"66","author":"H Zhao","year":"2019","unstructured":"Zhao H et al (2019) Liraglutide suppresses the metastasis of PANC-1 co-cultured with pancreatic stellate cells through modulating intracellular calcium content. Endocr J 66(12):1053\u20131062","journal-title":"Endocr J"},{"issue":"12","key":"11062_CR53","doi-asserted-by":"crossref","first-page":"E1431","DOI":"10.1152\/ajpendo.00017.2014","volume":"306","author":"H Zhao","year":"2014","unstructured":"Zhao H et al (2014) Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner. American Journal of Physiology-Endocrinology and Metabolism 306(12):E1431\u2013E1441","journal-title":"American Journal of Physiology-Endocrinology and Metabolism"},{"issue":"9","key":"11062_CR54","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1210\/en.2011-1201","volume":"152","author":"JA Koehler","year":"2011","unstructured":"Koehler JA, Kain T, Drucker DJ (2011) Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology 152(9):3362\u20133372","journal-title":"Endocrinology"},{"issue":"3","key":"11062_CR55","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3892\/or.2015.4476","volume":"35","author":"Y Zhang","year":"2016","unstructured":"Zhang Y et al (2016) Exenatide inhibits the growth of endometrial cancer Ishikawa xenografts in nude mice. Oncol Rep 35(3):1340\u20131348","journal-title":"Oncol Rep"},{"issue":"1","key":"11062_CR56","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4570-8","volume":"18","author":"R Kanda","year":"2018","unstructured":"Kanda R (2018) Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer. BMC Cancer 18(1):657","journal-title":"BMC Cancer"},{"issue":"6","key":"11062_CR57","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/a-1345-7890","volume":"71","author":"A Shadboorestan","year":"2021","unstructured":"Shadboorestan A et al (2021) Growth promotion and increased ATP-Binding cassette transporters expression by liraglutide in triple negative breast cancer cell line MDA-MB-231. Drug Res (Stuttg) 71(6):307\u2013311","journal-title":"Drug Res (Stuttg)"},{"issue":"4","key":"11062_CR58","first-page":"5202","volume":"17","author":"W Zhao","year":"2018","unstructured":"Zhao W et al (2018) Liraglutide inhibits the proliferation and promotes the apoptosis of MCF-7 human breast cancer cells through downregulation of microRNA-27a expression. Mol Med Rep 17(4):5202\u20135212","journal-title":"Mol Med Rep"},{"issue":"2","key":"11062_CR59","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10549-011-1585-0","volume":"132","author":"H Ligumsky","year":"2012","unstructured":"Ligumsky H et al (2012) The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Res Treat 132(2):449\u2013461","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"11062_CR60","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1210\/en.2017-00461","volume":"158","author":"C Iwaya","year":"2017","unstructured":"Iwaya C et al (2017) Exendin-4, a glucagonlike peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-\u03baB activation. Endocrinology 158(12):4218\u20134232","journal-title":"Endocrinology"},{"issue":"2","key":"11062_CR61","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1007\/s13277-015-4104-9","volume":"37","author":"G Fidan-Yaylal\u0131","year":"2016","unstructured":"Fidan-Yaylal\u0131 G (2016) Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells. Tumour Biol 37(2):2647\u20132653","journal-title":"Tumour Biol"},{"key":"11062_CR62","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.mce.2016.07.032","volume":"436","author":"W He","year":"2016","unstructured":"He W (2016) Exendin-4 inhibits growth and augments apoptosis of ovarian cancer cells. Mol Cell Endocrinol 436:240\u2013249","journal-title":"Mol Cell Endocrinol"},{"issue":"5\u20136","key":"11062_CR63","doi-asserted-by":"crossref","first-page":"186","DOI":"10.14712\/fb2020066050186","volume":"66","author":"RM Badi","year":"2020","unstructured":"Badi RM et al (2020) Exendin-4 induces cytotoxic autophagy in two ovarian cancer cell lines through inhibition of mTORC1 mediated by activation of AMPK and suppression of Akt. Folia Biol (Praha) 66(5\u20136):186\u2013203","journal-title":"Folia Biol (Praha)"},{"issue":"8","key":"11062_CR64","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1530\/EC-17-0294","volume":"6","author":"A Kosowska","year":"2017","unstructured":"Kosowska A (2017) Exenatide modulates tumor-endothelial cell interactions in human ovarian cancer cells. Endocr Connect 6(8):856\u2013865","journal-title":"Endocr Connect"},{"issue":"6","key":"11062_CR65","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/1440-1681.13288","volume":"47","author":"EF Khaleel","year":"2020","unstructured":"Khaleel EF (2020) Exendin-4 exhibits a tumour suppressor effect in SKOVR-3 and OVACR-3 ovarian cancer cells lines by the activation of SIRT1 and inhibition of NF-\u03baB. Clin Exp Pharmacol Physiol 47(6):1092\u20131102","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"11062_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21238976","author":"A Kosowska","year":"2020","unstructured":"Kosowska A et al (2021)  Sitagliptin modulates the response of ovarian cancer cells to chemotherapeutic agents. Int J Mol Sci 21(23): p. 8976. https:\/\/doi.org\/10.3390\/ijms21238976","journal-title":"Int J Mol Sci"},{"issue":"11","key":"11062_CR67","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1002\/cam4.3024","volume":"9","author":"Q Wang","year":"2020","unstructured":"Wang Q et al (2020) Sitagliptin affects gastric cancer cells proliferation by suppressing Melanoma-associated antigen-A3 expression through Yes-associated protein inactivation. Cancer Med 9(11):3816\u20133828","journal-title":"Cancer Med"},{"issue":"8","key":"11062_CR68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071716","volume":"8","author":"P Luciani","year":"2013","unstructured":"Luciani P et al (2013) Exendin-4 induces cell adhesion and differentiation and counteracts the invasive potential of human neuroblastoma cells. PLoS ONE 8(8):e71716","journal-title":"PLoS ONE"},{"key":"11062_CR69","volume":"65","author":"D Mao","year":"2021","unstructured":"Mao D et al (2021) Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: a translational case-control study. EBioMedicine 65:103242","journal-title":"EBioMedicine"},{"key":"11062_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165722","author":"M Kojima","year":"2020","unstructured":"Kojima M et al (2020) Glucagon-like peptide-1 receptor agonist prevented the progression of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis. Int J  Mol sci 21(16): p. 5722. https:\/\/doi.org\/10.3390\/ijms21165722","journal-title":"Int J Mol Sci"},{"issue":"12","key":"11062_CR71","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22220","volume":"32","author":"W Jiang","year":"2018","unstructured":"Jiang W (2018) Effect of sitagliptin, a DPP-4 inhibitor, against DENA-induced liver cancer in rats mediated via NF-\u03baB activation and inflammatory cytokines. J Biochem Mol Toxicol 32(12):e22220","journal-title":"J Biochem Mol Toxicol"},{"key":"11062_CR72","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.biopha.2016.05.005","volume":"82","author":"MK Tawfik","year":"2016","unstructured":"Tawfik MK, Mohamed MI (2016) Exenatide suppresses 1,2-dimethylhydrazine-induced colon cancer in diabetic mice: effect on tumor angiogenesis and cell proliferation. Biomed Pharmacother 82:106\u2013116","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"11062_CR73","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1002\/ijc.28260","volume":"133","author":"AP Femia","year":"2013","unstructured":"Femia AP et al (2013) Long-term treatment with sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats. Int J Cancer 133(10):2498\u20132503","journal-title":"Int J Cancer"},{"issue":"1","key":"11062_CR74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12672-013-0163-9","volume":"5","author":"MA Honors","year":"2014","unstructured":"Honors MA, Kinzig KP (2014) Chronic exendin-4 treatment prevents the development of cancer cachexia symptoms in male rats bearing the Yoshida sarcoma. Horm Cancer 5(1):33\u201341","journal-title":"Horm Cancer"},{"issue":"1","key":"11062_CR75","volume":"7","author":"L He","year":"2017","unstructured":"He L (2017) Exendin-4 exhibits enhanced anti-tumor effects in diabetic mice. Sci Rep 7(1):1791","journal-title":"Sci Rep"},{"issue":"1\u20133","key":"11062_CR76","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.regpep.2010.04.005","volume":"163","author":"D Prabakaran","year":"2010","unstructured":"Prabakaran D et al (2010) Glucose-dependent insulinotropic polypeptide stimulates the proliferation of colorectal cancer cells. Regul Pept 163(1\u20133):74\u201380","journal-title":"Regul Pept"},{"issue":"4","key":"11062_CR77","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000330447","volume":"94","author":"B Waser","year":"2011","unstructured":"Waser B et al (2011) Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy. Neuroendocrinology 94(4):291\u2013301","journal-title":"Neuroendocrinology"},{"issue":"4","key":"11062_CR78","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2337\/db13-1268","volume":"63","author":"KD Chadwick","year":"2014","unstructured":"Chadwick KD et al (2014) Occurrence of spontaneous pancreatic lesions in normal and diabetic rats: a potential confounding factor in the nonclinical assessment of GLP-1-based therapies. Diabetes 63(4):1303\u20131314","journal-title":"Diabetes"},{"key":"11062_CR79","doi-asserted-by":"crossref","DOI":"10.1177\/0963689720927392","volume":"29","author":"H Deng","year":"2020","unstructured":"Deng H et al (2020) Long-term liraglutide administration induces pancreas neogenesis in adult T2DM mice. Cell Transplant 29:0963689720927392","journal-title":"Cell Transplant"},{"issue":"7","key":"11062_CR80","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.2337\/db12-1686","volume":"62","author":"AE Butler","year":"2013","unstructured":"Butler AE et al (2013) Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 62(7):2595\u20132604","journal-title":"Diabetes"},{"issue":"12","key":"11062_CR81","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/dom.12766","volume":"18","author":"S Ueberberg","year":"2016","unstructured":"Ueberberg S (2016) Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies. Diabetes Obes Metab 18(12):1253\u20131262","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"11062_CR82","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1210\/en.2011-1864","volume":"153","author":"LW Madsen","year":"2012","unstructured":"Madsen LW (2012) GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology 153(3):1538\u20131547","journal-title":"Endocrinology"},{"issue":"1\u20133","key":"11062_CR83","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.regpep.2012.08.016","volume":"179","author":"H Kissow","year":"2012","unstructured":"Kissow H (2012) Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regul Pept 179(1\u20133):91\u2013100","journal-title":"Regul Pept"},{"issue":"22","key":"11062_CR84","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1158\/0008-5472.CAN-18-0687","volume":"78","author":"JW Russo","year":"2018","unstructured":"Russo JW (2018) Downregulation of dipeptidyl peptidase 4 accelerates progression to Castration-Resistant prostate cancer. Cancer Res 78(22):6354\u20136362","journal-title":"Cancer Res"},{"issue":"3","key":"11062_CR85","first-page":"209","volume":"42","author":"H Wenjing","year":"2017","unstructured":"Wenjing H et al (2017) Exendin-4 does not modify growth or apoptosis of human colon cancer cells. Endocr Res 42(3):209\u2013218","journal-title":"Endocr Res"},{"issue":"6","key":"11062_CR86","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2337\/dc18-2028","volume":"42","author":"MA Bethel","year":"2019","unstructured":"Bethel MA et al (2019) Changes in serum calcitonin concentrations, incidence of medullary thyroid carcinoma, and impact of routine calcitonin concentration monitoring in the exenatide study of cardiovascular event lowering (EXSCEL). Diabetes Care 42(6):1075\u20131080","journal-title":"Diabetes Care"},{"issue":"2","key":"11062_CR87","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/EDE.0000000000000793","volume":"29","author":"D Abrahami","year":"2018","unstructured":"Abrahami D et al (2018) Incretin-based drugs and the incidence of colorectal cancer in patients with type 2 diabetes. Epidemiology 29(2):246\u2013253","journal-title":"Epidemiology"},{"key":"11062_CR88","first-page":"i5340","volume":"355","author":"BM Hicks","year":"2016","unstructured":"Hicks BM et al (2016) Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK clinical practice research datalink. BMJ 355:i5340","journal-title":"BMJ"},{"issue":"4","key":"11062_CR89","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/dom.13597","volume":"21","author":"C Liang","year":"2019","unstructured":"Liang C et al (2019) Exenatide use and incidence of pancreatic and thyroid cancer: a retrospective cohort study. Diabetes Obes Metab 21(4):1037\u20131042","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"11062_CR90","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/dom.13739","volume":"21","author":"D Funch","year":"2019","unstructured":"Funch D (2019) Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population. Diabetes Obes Metab 21(8):1837\u20131848","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"11062_CR91","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1097\/MPA.0000000000002197","volume":"51","author":"A Krishnan","year":"2022","unstructured":"Krishnan A et al (2022) Glucagon-like peptide 1-based therapies and risk of pancreatic cancer in patients with diabetes and obesity. Pancreas 51(10):1398\u20131403","journal-title":"Pancreas"},{"issue":"12","key":"11062_CR92","doi-asserted-by":"crossref","first-page":"19057","DOI":"10.18632\/oncotarget.12137","volume":"8","author":"CH Tseng","year":"2017","unstructured":"Tseng CH (2017) Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes. Oncotarget 8(12):19057\u201319064","journal-title":"Oncotarget"},{"issue":"3","key":"11062_CR93","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.clbc.2016.11.002","volume":"17","author":"CH Tseng","year":"2017","unstructured":"Tseng CH (2017) Sitagliptin may reduce breast cancer risk in women with type 2 diabetes. Clin Breast Cancer 17(3):211\u2013218","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"11062_CR94","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc22-1148","volume":"46","author":"J Bezin","year":"2023","unstructured":"Bezin J et al (2023) GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care 46(2):384\u2013390","journal-title":"Diabetes Care"},{"key":"11062_CR95","doi-asserted-by":"crossref","first-page":"k4880","DOI":"10.1136\/bmj.k4880","volume":"363","author":"D Abrahami","year":"2018","unstructured":"Abrahami D et al (2018) Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ 363:k4880","journal-title":"BMJ"},{"issue":"1","key":"11062_CR96","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/eci.12570","volume":"46","author":"CH Tseng","year":"2016","unstructured":"Tseng CH (2016) Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes. Eur J Clin Invest 46(1):70\u201379","journal-title":"Eur J Clin Invest"},{"key":"11062_CR97","unstructured":"Elsayed NA et al (2024) Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes. Diabetes Care 47."},{"key":"11062_CR98","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.taap.2017.02.010","volume":"320","author":"W van den Brink","year":"2017","unstructured":"van den Brink W (2017) Prediction of thyroid c-cell carcinogenicity after chronic administration of GLP1-R agonists in rodents. Toxicol Appl Pharmacol 320:51\u201359","journal-title":"Toxicol Appl Pharmacol"},{"key":"11062_CR99","doi-asserted-by":"crossref","unstructured":"Faisal M et al S(1909) Association of Glucagon-Like Peptide-1 Therapies and Risk of Cancer in Liver Transplant Patients. American Journal of Gastroenterology, 2024. 119: pp. S1368\u2013S1368","DOI":"10.14309\/01.ajg.0001037004.02896.90"},{"key":"11062_CR100","doi-asserted-by":"crossref","unstructured":"Betchvaia V et al (2024) #1677365 A case of a 58-year-old man with type 2 DM who was diagnosed with pancreatic adenocarcinoma after treatment with Tirzepatide. Endocrine Practice, 30(5, Supplement): p. S26","DOI":"10.1016\/j.eprac.2024.03.168"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11062-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-11062-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11062-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T05:04:33Z","timestamp":1766898273000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-11062-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["11062"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-11062-5","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"965"}}